For This Week on Estimize our CEO Leigh Drogen is joined by Joe McCann, a buy-side biotech analyst and the Founder of Slingshot Insights. Joe tells us why he believes the biotech boom still has plenty of legs and Leigh and Joe discuss how to value pharmaceutical stocks.
The discussion covers specific names including Gilead Sciences (GILD), BioDelivery Sciences (BDSI), Retrophin (RTRX), and Auspex Pharmaceuticals (ASPX).
Comments
Log in or sign up to join the conversation.